z-logo
Premium
HuR in pheochromocytomas and paragangliomas – overexpression in verified malignant tumors
Author(s) -
Leijon Helena,
Salmenkivi Kaisa,
Heiskanen Ilkka,
Hagström Jaana,
Louhimo Johanna,
Heikkilä Päivi,
Ristimäki Ari,
Paavonen Timo,
Metso Saara,
Mäenpää Hanna,
Haglund Caj,
Arola Johanna
Publication year - 2016
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12571
Subject(s) - immunohistochemistry , cancer research , tissue microarray , pathology , pheochromocytoma , messenger rna , cytoplasm , neural crest , biology , medicine , gene , microbiology and biotechnology , biochemistry
Pheochromocytomas and paragangliomas are rare, neural crest‐originating, neuroendocrine tumors. HuR is an mRNA‐binding protein of the ELAV/Hu‐protein family, which participates in posttranscriptional regulation of many cancer‐associated genes. HuR expression has been connected with aggressive behavior of several malignancies. Cyclooxygenase‐2 (COX‐2) is also expressed in several malignant tumors, and its expression is regulated by HuR. Tissue microarray of 153 primary pheochromocytomas and paragangliomas was investigated for the expression of HuR and COX‐2 proteins by immunohistochemistry using two different HuR antibodies (HuR19F12 and HuR3A). In these tumors, the expression of both intranuclear and cytoplasmic HuR was detectable. Increased cytoplasmic HuR expression was significantly associated with metastatic tumors. Increased COX‐2 and MIB‐1 expression also was associated with metastatic potential, and moreover, HuR and COX‐2 expression correlated with each other. Our data suggest that increased expression of HuR protein is associated with metastatic potential of paragangliomas and pheochromocytomas, and COX‐2 seems to be a target of HuR.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here